Update shared on05 Sep 2025
With no change in either the discount rate or future P/E, Maximus’s consensus analyst price target remained stable at $105.00.
What's in the News
- Maximus completed its $527.74 million share buyback program, repurchasing 11.95% of shares, but made no additional repurchases between April and June 2025.
- The company raised its 2025 revenue guidance by $100 million at the midpoint, now expecting $5.375–$5.475 billion.
- Awarded a $77 million contract by the U.S. Air Force to deliver cybersecurity and cloud-based services supporting DoD operational readiness.
- Selected to continue as the Medicaid/CHIP enrollment broker for West Virginia and highlighted success in improving customer satisfaction and supporting Social Determinants of Health initiatives.
- Expanded PASRR services through a new Colorado contract, a Delaware renewal, and launch in Louisiana, now supporting 15 states.
Valuation Changes
Summary of Valuation Changes for Maximus
- The Consensus Analyst Price Target remained effectively unchanged, at $105.00.
- The Discount Rate for Maximus remained effectively unchanged, at 7.05%.
- The Future P/E for Maximus remained effectively unchanged, at 11.92x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.